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Abstract: Oleocanthal (OLC), a phenolic compound of extra virgin olive oil (EVOO), has emerged
as a potential therapeutic agent against a variety of diseases due to its anti-inflammatory activity.
The aim of the present study is to explore its in vivo intestinal absorption and metabolism. An
in situ perfusion technique in rats was used, involving simultaneous sampling from the luminal
perfusate and mesenteric blood. Samples were analysed by UHPLC–MS–MS for the presence
of oleocanthal (OLC) and its metabolites. OLC was mostly metabolized by phase I metabolism,
undergoing hydration, hydrogenation and hydroxylation. Phase II reactions (glucuronidation of
hydrogenated OLC and hydrated metabolites) were observed in plasma samples. OLC was poorly
absorbed in the intestine, as indicated by the low effective permeability coefficient (2.23 ± 3.16 × 10−5
cm/s) and apparent permeability coefficient (4.12 ± 2.33 × 10−6 cm/s) obtained relative to the values of
the highly permeable reference compound levofloxacin (LEV). The extent of OLC absorption reflected
by the area under the mesenteric blood-time curve normalized by the inlet concentration (AUC) was
also lower than that of LEV (0.25 ± 0.04 vs. 0.64 ± 0.03, respectively). These results, together with the
observed intestinal metabolism, suggest that OLC has a moderate-to-low oral absorption; but higher
levels of OLC are expected to reach human plasma vs. rat plasma.
Keywords: bioavailability; metabolism; in situ perfusion; permeability; extra virgin olive oil;
secoiridoids
1. Introduction
The secoiridoids are the most abundant and complex family of phenolic compounds in extra virgin
olive oil (EVOO). The main secoiridoids compounds identified in EVOO are the monoaldehydic forms
of oleuropein (3,4-DHPEA-EA) and ligstroside aglycones (p-HPEA-EA) and the dialdehydic forms of
their decarboxymethylated derivatives, oleacein (3,4-DHPEA-EDA) and oleocanthal (p-HPEA-EDA) [1].
Since its identification in 1993 [2], oleocanthal (OLC) has been targeted by numerous in vitro and in vivo
studies aiming to understand the health effects of EVOO consumption [3]. The data obtained on OLC
thus far have clearly demonstrated its anti-inflammatory activity [4] as well as its role in the prevention
of various pathologies with an inflammatory component [5]. OLC also exerts a neuroprotective
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effect in conditions such as Alzheimer’s disease [6,7] and has shown promising chemotherapeutic
properties, reducing cell proliferation and promoting cell death through different mechanisms of
action [8]. Antirheumatic activity has been demonstrated in in vitro studies, in which OLC ameliorated
osteoarthritis and rheumatoid arthritis [3]. Additionally, OLC has been shown to be beneficial for
cardiovascular health, improving endothelial function in patients with early atherosclerosis and
reducing platelets in healthy men [3].
Given this broad and promising range of biological effects, most research on OLC has been focused
on its health properties and the agronomic and processing factors that promote its presence in EVOO [9].
Information on the bioavailability of this phenolic compound would help determine the mechanisms
behind its biological activities; however, none have been reported to date. The bioavailability of
ingested phenolic compounds can be influenced by factors such as diet, genomic profile, enzymatic
activity and colonic microflora [3], but it also depends on the extent of absorption and metabolism
after ingestion. In this context, many in vitro and in vivo models for estimating human intestinal
permeability and first-pass metabolism have been developed [10,11].
Before reaching the bloodstream, drugs and nutrients administered orally are usually absorbed
from the small intestine. Although different factors (physicochemical, physiological and the matrix
effect) can affect the rate and extent of absorption, the absorption of orally administered drugs is mainly
determined by the solubility/dissolution of the molecule in the gastrointestinal environment as well as
the permeability of the gastrointestinal wall [12]. In situ intestinal perfusion with venous sampling
models facilitates a direct determination of drug absorption through the enterocytes on the basis of
appearance kinetics in pre-hepatic blood [13]. This experimental model, which includes a mucus layer,
blood irrigation and innervation, has been widely used due to its similarity with in vivo conditions [14].
It also allows the study of the role of transporters in absorption through the biorelevant expression of
proteins (both transporters and intestinal enzymes) [12,15] and has full metabolic capacity for up to
120 min after intestinal isolation [16].
The objectives of the present work are to study the intestinal absorption and metabolism of
OLC using an in situ perfusion technique in rats involving simultaneous sampling from the luminal
perfusate and mesenteric blood. As a reference, the highly permeable drug levofloxacin (LEV) was
included in the study. In addition, an intestinal metabolic profile of OLC was determined.
2. Materials and Methods
2.1. Reagents and Materials
OLC was purchased from PhytoLab GmbH (Vestenbergsgreuth, Germany). Phenol red, LEV,
heparin sodium salt from porcine intestinal mucosa, Hanks’ Balanced Salt Solution (HBBS) and
HEPES 1 M solution were obtained from Sigma Aldrich (Madrid, Spain). Pentobarbital sodium
200 mg/mL (Dolethal) was purchased from Vétoquinol (Madrid, Spain) and isoflurane from
Laboratorios Esteve (Barcelona, Spain). The reagents, methanol, acetonitrile and formic acid, were
purchased from Sigma-Aldrich.
2.2. Animals
These studies were conducted following a protocol approved by the Animal Experimentation
Ethics Committee of the University of Barcelona, Spain (trial no. CEEA 124/16) and Generalitat de
Catalunya (no. 6435, 27 June 2019). For each compound, four Sprague–Dawley rats (body weight
306 ± 31 g) were used per intestinal perfusion with the mesenteric blood sampling experiment, and
four (~350–400 g) were used as blood donors.
2.3. Single-Pass Intestinal Perfusion Studies
OLC was assayed at 0.1 mg/mL (328.94 µM) in transport medium (TM pH 7, 9.7 g/L HBSS buffered
with HEPES 10 mM). This concentration was chosen by taking into account both the OLC concentration
Pharmaceutics 2020, 12, 134 3 of 14
in EVOO (around of 200 mg/kg) and the daily ingestion of EVOO recommended by the European
Food Safety Authority (EFSA) (at least 5 mg of hydroxytyrosol and its derivatives per 20 g of olive
oil) [17] and also considering the limit of quantification of the analytical technique. LEV was assayed
at 3 mg/mL, according to its high dose strength, in 250 mL TM.
Single-pass intestinal perfusion was performed in anesthetized rats according to the method
described by Brouwers et al. [15], with simultaneous sampling from the luminal perfusate and
mesenteric blood.
2.3.1. Donor Blood
On the day of the perfusion, one or two rats (350–400 g) were anesthetised by isoflurane inhalation,
and the whole blood was collected via cardiac puncture. The blood was diluted with heparin (50 u/mL
TM) to 80% blood and kept in a 20 mL syringe for the in situ intestinal perfusion experiment.
2.3.2. Surgical Procedure
Anaesthesia was induced by intraperitoneal injection of pentobarbital sodium (60 mg/kg BW).
The rats were then placed on a homeothermic blanket to maintain the body temperature at 37 ◦C.
First, under general anaesthesia, the left jugular vein was cannulated with a heparinised (50 IU/mL)
0.5 × 0.9 mm/20 G catheter (Cavafix® MT, Braun Medical S.A., Barcelona, Spain) for infusion of donor
blood. Second, a midline abdominal incision was made to isolate approximately 10 cm of the ileum
using the ileocecal junction as a point of reference. Two glass cannulas (o.d. 4 mm, i.d. 3 mm, Duran®,
Vidrafoc, Barcelona, Spain) were inserted at the proximal and distal ends of the isolated segment.
The segment was rinsed by injection TM to remove the content until the solution came out clear.
Next, the inlet cannula was connected to polyethylene tubing (i.d. 3 mm), which aspirated the tested
solution (OLC or LEV) using a peristaltic pump (Minipuls3, M312 model, Gilson, Le Bel, France).
Finally, the mesenteric vein draining blood from the intestinal segment was cannulated by inserting
approximately 1 cm of a catheter (BD Insyte-W 24GA 0.7 × 19 mm, Becton Dickinson, Sangüesa S.A.,
Cornellà de Llobregat, Spain). The cannula was secured with a knot and connected to a silicone tube
(i.d. 0.64 mm; o.d. 1.19 mm, Freudenberg Medical Europe, VWR International Eurolab S.L., Llinars
del Vallés, Spain) that allowed blood to flow into the heparinised tubes. Care was taken to handle
the small intestine gently to maintain normal blood supply. The exposed areas (both the jugular and
abdomen) were wet with TM at 37 ◦C and covered with Parafilm® to keep them warm and moistened
during the experiment.
2.3.3. Intestinal Perfusion
The experiments were carried out in a laboratory room with infrared light to avoid oxidation of
OLC. The procedure was started by delivering the perfusion solution containing OLC (0.1 mg/mL) or
LEV (3 mg/mL) (in separate experiments) and phenol red (0.1 mg/mL) at a flow rate of 1 mL/min to the
intestinal segment previously cannulated. Simultaneously, the blank donor rat blood was supplied at a
rate of 0.3 mL/min using a syringe pump (Injectomat MC Agilia, Fresenius Kabi España, Barcelona,
Spain). Samples of both the intestinal lumen and mesenteric blood were collected at the same time.
Simultaneously, the outflow perfusate was collected in 1.5 mL amber vials at 5 min intervals for 60 min,
and the blood was collected in pre-weighted lithium-heparinised tubes (BD Vacutainer). At the end of
the experiment, the animal was euthanised by injection of air into the jugular, and the length of the
intestinal segment was measured. Next, the perfusion samples were centrifuged (7516 g for 10 min at
4 ◦C), and the supernatant was stored at −80 ◦C until analysis. The tubes with blood samples were
weighted and centrifuged (7516.3 g for 10 min at 4 ◦C), and the plasma was collected and stored at
−80 ◦C until solid-phase extraction (SPE).
The stability of the test products, sampled at different times, was tested in the perfusion solution
at 37 ◦C for 60 min.
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2.4. Oleocanthal Analysis
2.4.1. Solid-Phase Extraction (SPE) of OLC from Plasma
Extraction of OLC and its metabolites from plasma samples was carried out using an Oasis®
HLB 30-mm (30 mg) 96-well plate (Waters, Wexford, Ireland), following the methodology proposed
by Orrego-Lagarón and colleagues [18], with some modifications. Initially, the samples were thawed
and centrifuged (7516 g, 10 min at 4 ◦C). The pre-treatment of samples consisted of diluting an exact
volume of the supernatants to 1 mL with 0.1% of formic acid in water (v/v). The plate was activated
with methanol and water containing 1% (v/v) formic acid. After loading the plasma mixture, the plates
were cleaned by adding 1 mL 1% formic acid in water, followed by 1 mL methanol/water (5:95). The
retained compounds were then eluted with 1 mL methanol acidified with 0.1% formic acid (v/v), and
the resulting fraction was evaporated to dryness at room temperature under a stream of N2. Finally, the
samples were reconstituted with 100 µL of methanol containing 0.1% (v/v) formic acid. The extraction
was performed in a darkened room with a red safety light to avoid oxidation of the analytes.
2.4.2. LC–ESI–LTQ–Orbitrap–MS
An LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Hemel Hempstead, UK) equipped
with an ESI source in negative mode was used for accurate mass measurements. The operation
parameters were the following: source voltage, 4 kV; capillary temperature, 275 ◦C (FT Automatic gain
control (AGC) target 5 × 105 for MS mode and 5 × 104 for MSn mode). The arbitrary units were used
for sheath gas, auxiliary gas and sweep gas (20, 10 and 2, respectively). All samples were analysed
in full scan mode at a resolving power of 30,000 at m/z 400, and data-dependent MS/MS events were
acquired at a resolving power of 15,000. The most intense ions detected during full scan MS triggered
data-dependent scanning. Ions that were not intense enough for a data-dependent scan were analysed
in MSn mode with the same orbitrap resolution (15,000 at m/z 400). An isolation width of 100 amu was
used, and precursors were fragmented by collision-induced dissociation C-trap (CID) with normalized
collision energy (35 V) and an activation time of 10 ms. The mass range in FTMS mode was from m/z
100 to 1000. The system was controlled by XCalibur software v2.0.7 (ThermoFisher Scientific).
An Accela chromatograph (Thermo Scientific, Hemel Hempstead, UK) equipped with a quaternary
pump, a photodiode array detector (PDA) and a thermostated autosampler was used for the liquid
chromatography analysis. The injection volume was 2 µL, the flow rate was set to 0.6 mL/min and the
separations were carried out on an AcquityTM UPLC® BEH C18 Pre-Column (2.1 × 5 mm, i.d., 1.7 µm
particle size) and an AcquityTM UPLC® BEH C18 Column (2.1 × 50 mm, i.d., 1.7 µm particle size)
(Waters Corporation®, Wexford, Ireland) at 50 ◦C. The mobile phases consisted of methanol (A) and
H2O (B), both with 0.1% of formic acid. The elution was performed by means of an increasing linear
gradient (v/v) of B (t (min), %B), as follows: (0, 100); (2, 100); (6, 46.4); (8, 0); (9, 0); (9.1, 100); (11, 100).
2.4.3. UHPLC–ESI–MS/MS
All luminal, plasma and stability samples were analysed by ultra-high-performance liquid
chromatography/electrospray ionization tandem mass spectrometry (UHPLC–ESI–MS/MS). The
quantification of OLC and its metabolites was performed using an AcquityTM UPLC (Waters; Milford,
Massachusetts, USA) coupled to an API 3000 triple-quadruple mass spectrometer (ABSciex, Concord,
Ontario, Canada) with a turbo ion spray source. The chromatographic separation of the parent
compound and its metabolites were achieved using the same conditions (flow rate, column, injection
volume and gradient conditions) as in LC–ESI–LTQ–Orbitrap–MS (Section 2.4.2).
The ionization of all compounds was performed using an electrospray interface operating in the
negative mode [M–H] in the multiple monitoring mode (MRM). The arbitrary units were used for the
nebulizer (10), curtain (12) and drying gas (450 ◦C) using N2; the capillary voltage was −3500 V. The
declustering, focusing and entrance potential and the collision energy were optimised to detect OLC
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and oleacein with the highest signal (see Table S1 for a detailed description of each compound). The
system was controlled by Analyst version 1.4.2 software supplied by Applied Biosystems.
The calibration curves were prepared in TM and rat plasma (0–150 and 0–50 µg/mL, respectively)
using OLC. The metabolites—in the absence of the reference standard—were evaluated by a screening
method that includes a relative comparison of metabolite abundance (peak area ratio of metabolite/dosed
parent compound OLC) [19,20].
2.5. Levofloxacin Analysis
A validated HPLC method was used to determine the concentration of LEV in luminal and plasma
samples. The HPLC system consisted of two Waters 515 pumps, a 717 plus Waters auto sampler and a
Waters dual absorbance detector 2487 with UV detection (Waters Chromatography S.A., Barcelona,
Spain). The separation was carried out using a Hypersil® Elite C18 column (150 mm × 4.6 mm i.d.,
particle size 5 µm, ThermoFisher Scientific) with the flow rate at 0.8 mL/min. The mobile phase was
isocratic, consisting of 1% triethylamine (pH 3.0 adjusted with phosphoric acid) and acetonitrile (86/14,
v/v). The UV detection wavelength was set at 293 nm. The run time was 10 min for lumen samples and
12 min for plasma samples, and the injection volume was 10 µL. The calibration curves were prepared
in TM and plasma and were linear over the concentration ranges 5–100 and 10–100 µg/mL, respectively.
For plasma samples, the procedure of Watabe et al. with some modifications was followed [21].
The standard solutions for the calibration curves were prepared from three stock standard solutions,
using LEV (200 µg/mL and 1 mg/mL in TM) and ciprofloxacin as the internal standard (1 mg/mL
in HCL 0.1 N). Different volumes of the LEV stock solutions (between 20 and 80 µL) and 16 µL of
ciprofloxacin (1 mg/mL) were added to Eppendorf tubes, and drug-free rat plasma was incorporated
to a total volume of 200 µL.
A liquid–liquid extraction was achieved using 200 µL calibration standards or samples mixed
with 100 µL 6% (w/v) perchloric acid. Each mixture was vortexed for 30 s. Then, 100 µL of methanol
was added to the above mixture, which was vortexed again for 30 s. The mixture was centrifuged at
9900 rpm for 12 min at room temperature, and 10 µL of the supernatant was injected into the HPLC.
The final concentration of ciprofloxacin in the samples was 40 µg/mL. The retention times for LEV and
ciprofloxacin were 7.8 ± 0.2 min and 8.7 ± 0.3 min, respectively.
2.6. Phenol Red Analysis
The concentration of phenol red in luminal samples from the in situ experiments with LEV was
determined using a colorimetric assay. In each microplate well, 200 µL samples diluted 1/10 were
added. The dilution was prepared with a 50 µL sample, NaOH 1 N (20 µL) and TM (430 µL). The
absorbance at 558 nm was measured with a multidetector microplate reader (Biotek Instruments Inc.,
Winooski, VT, USA) equipped with Gen5 2.00 data analysis software. The calibration curves of phenol
red were prepared in the same dissolution medium as the luminal samples at the concentrations of 24,
12, 6 and 3 µg/mL.
The concentration of phenol red in lumen samples from the in situ experiments with OLC was
analysed by UHPLC–ESI–MS/MS in the same conditions as the OLC.
2.7. Data Analysis
The effective permeability coefficient (Peff, cm/s) through the rat ileum was determined by
Equation (1):
Peff =
−∅in
2piRL
× Ln Cin
Cout.cor
(1)
where ∅in is the perfusion solution flow (1 mL/min), Cin and Cout.cor are the respective inlet and
corrected outlet steady-state concentrations of the tested product, R is the radius of the intestinal
segment (set to 0.2 cm) and L is the length of the intestinal segment determined after completion of the
perfusion experiment.
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The outlet concentrations were corrected for water transport by measuring the nonabsorbed and
nonmetabolized phenol red marker according to Equation (2):
Cout.cor = Cout × CPRinCPRout (2)
where Cout is the concentration of OLC or LEV in the perfusate at the specified time interval and CPRin
and CPRout is the phenol red concentration in the inlet and outlet buffer solution at the specific time
interval, respectively.
The apparent permeability coefficient (Papp, cm/s) was calculated using Equation (3):
Papp =
dQ
dt
× 1
A×C0 (3)
where Q is the cumulative amount of OLC or LEV appearing in the mesenteric blood as a function of
time t in steady-state conditions, A is the surface area of the exposed intestinal segment and C0 is the
OLC or LEV initial concentration in the perfusate.
All in situ perfusion experiments were replicated in four rats, and the results were normalised to
a 10-cm intestinal segment.
As a measure of the extent of absorption, the areas under the plasma concentration (normalised
by the inlet concentration) time curves (AUC) for the intestinal perfusions were calculated using
WinNonlin Professional software version 3.3 (Pharsight Corporation, Mountain View, USA) from time
0 to 60 min using the linear trapezoidal method.
Data are presented as mean and standard deviation (SD). Statistical analysis was performed using
SAS (version 9.4). Statistical differences in the peak area ratio metabolite/parent OLC between different
time periods were analysed using a one-way ANOVA. The Peff, Papp and AUC of OLC and LEV were
compared using a Mann–Whitney U-test. Differences were considered significant at p < 0.05.
3. Results and Discussion
3.1. Intestinal Metabolic Profile of Oleocanthal
3.1.1. Identification of Metabolites
To identify the OLC metabolites in plasma and perfusion samples, we initially used
LC–ESI–LTQ–Orbitrap–MS in FTMS mode, followed by a data-dependent scan. Combining the
FTMS scan and MSn experiments, four metabolites were identified in plasma and two metabolites
(hydroxylated and hydrated) in perfusion samples. The proposed chemical structures are depicted
in Figure 1. These metabolites and their retention times (RT), accurate masses, major fragments,
error (mDa) and molecular formulas are shown in Table 1. Metabolite identification is important to
reveal possible metabolic instability, causing extensive first-pass intestinal metabolism and poor oral
bioavailability [22].
Table 1. Oleocanthal (OLC) and its metabolites identified in lumen and plasma samples using
an LTQ–Orbitrap.
Compound RT (min) Accurate Mass Major Fragments Error (mDa) Molecular Formula
OLC 5.8 303.1230 285.1125/179.0708 0.48 C17H19O5
OLC + OH 6.49 319.1180 153.0271/183.0665 0.16 C17H19O6
OLC + H2O 6.36 321.1344 201.0759/183.0665 0.88 C17H21O6
OLC + H2 + glucuronide 5.83 481.1719 217.0859/185.0509 0.05 C23H29O11
OLC+ H2O + glucuronide 5.74 497.1666 321.1344/201.0759 0.17 C23H29O12
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3.1.2. Phase I Metabolism
The intestine is the most important extrahepatic site for drug biotransformation [10]. When
crossing enterocytes, EVOO phenolic compounds are subjected to extensive first-pass metabolism
through phase I/II biotransformation [23]. In our study, the two metabolites corresponding to phase I
metabolism (hydration and hydroxylation identified in perfusion and plasma samples) are shown in
Figures 2 and 3, respectively. Compared to OLC, the relative abundance of metabolites was higher in
plasma than in the lumen.
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These results are consistent with the work of Garcia-Villalba et al. [24], who studied the urinary
excretion of phenolic compounds after olive oil intake in humans. They identified, among others,
hydroxylated and hydrated metabolites from phase I reactions in urine; however, the samples were
discarded because the metabolites could have been related to hydroxytyrosol derivatives. Hydrogenated
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and hydrated (+glucuronidation) metabolites were additionally identified from phase II reactions with
the same accurate mass. In the current study, we can confirm that they were direct metabolites of
OLC. In another study [25], the hydrated metabolite was also identified in plasma samples after the
ingestion of EVOO.Pharmaceutics 2020, 12, 134 8 of 14 
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As shown in Figures 2 and 3, the most abundant phase I metabolite found in the samples was the
hydrated form, with higher levels in plasma than in the lumen (p < 0.05). The metabolites in the lumen
can originate from the microbiome, since many bacterial cytochromes P450 (CYP) are soluble [26], or
from CYP of the enterocytes. This family of metabolic enzymes are present in the epithelium of the
small intestine [27] and are responsible for the oxidative biotransformation of xenobiotics and other
compounds [28]. The absorbed and metabolized OLC would be subsequently secreted to the intestinal
lumen by efflux transporters.
The hydrogenated metabolites were found in a glucuronidated form in plasma but not in the lumen.
Even when considering the differences between rat and human microsomal activity, hydrogenation
seems to be an important phase I metabolic route for secoiridoids [25]. This reduction reaction is
catalysed by NADPH-dependent aldo-keto reductases (AKR) located in the small intestine epithelium
and can occur because OLC contains an open dialdehydic form of the attached elenolic acid molecule.
During phase I metabolism, the reduction of aldehydes and ketones to primary and secondary alcohols,
respectively, are formal functionalisation reactions and are involved in endogenous and xenobiotic
compounds that have these carbonyl groups [29]. Moreover, the redox potential in the intestine favours
the reduction reaction due to low oxygen tension, which provides a reducing environment, whereas
oxidation is favoured in tissues such as the liver [30].
3.1.3. Phase II Metabolism
Th a pearance i pl sma of met bolites arising from phase II reactions (glucuronidation of
hydrogenated and hydrated metabolit s) from time 0 (at the start of the in situ intestinal perfusion) t
60 in are depicted in Figure 3. The main phase II metabolite detected in plasma samples was th
hydrat metab lite with constant relative abundance over time (p < 0.05).
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The glucuronidation of hydrogenated and hydrated metabolites likely occurs after
oxidative-reductive metabolism because although drugs can undergo phase I and II reactions
simultaneously, one of the pathways usually dominates [31]. The glucuronidation reaction mediates the
transfer of a glucuronyl moiety from the ubiquitous co-substrate UDP-glucuronic acid to hydrophobic
molecules with one or more electrophilic groups which serve as acceptors [32]. Similar results
indicating that secoiridoids (3,4-DHPEA-EDA and 3,4-DHPEA-EA) undergo hydrogenation followed
by glucuronidation have been previously reported in perfused segments of jejunum and ileum in
rats [16]. Based on their high polarity and molecular weight, both phase II metabolites would be
secreted to the mesenteric blood by transporters. A proposal of what could happen at the intestinal
level is shown in Figure 4.
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3.2. Perfusion Experiments and Intestinal Permeability of Oleocanthal
Prior to carrying out the intestinal permeability study, it is necessary to check the stability of
the test compound and the reference standard in the perfusion solution at 37 ◦C during the test time
(1 h). Both OLC and LEV remained stable in the perfusion solution (p < 0.05) during the experiments
(Figure S1).
The intestinal permeability coefficient (Peff) is widely used as part of a general screening process
for orally administered drugs to study their intestinal absorption. It is important to determine the
intestinal permeability of OLC, a component of EVOO (and therefore of the Mediterranean diet), of
which many beneficial health properties have been reported [33]. In this work, to assess both the
intestinal absorption and potential intestinal first-pass metabolism of OLC, simultaneous samples were
collected from both the intestinal lumen and the mesenteric circulation. The concentration of OLC and
the relative abundance of metabolites was determined (see Section 3.1). In addition, to ascertain if the
results obtained for OLC imply high or low absorption/permeability, a group of rats perfused with
LEV was also included in the study. According to the current Biopharmaceutics Classification System
(BCS) [34], LEV is a highly permeable drug with an oral bioavailability close to 100% [35,36]. When
assayed at 3 mg/mL in Caco-2 cells [35], it produced an apparent permeability coefficient similar to
that of metoprolol, another reference drug of high permeability.
Surprisingly, despite the myriad of potential health benefits attributed to EVOO phenolic
compounds, there is currently little information available on the intestinal permeability coefficients of
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secoiridoids, especially OLC. Previous studies in rats have observed poor absorption of secoiridoids in
the intestine perfused with oleuropein in iso-osmotic conditions, although it was significantly greater
under hypotonic conditions (1.47 × 10−6 and 5.92 × 10−6 cm/s, respectively) [37]. Differentiated Caco-2
cell monolayers as a model system have been demonstrated to be highly permeable for hydroxytyrosol
(12.4 ± 0.9 × 10−6 cm/s) [38].
The permeability coefficients of OLC (0.1 mg/mL) and LEV (3 mg/mL) in the rat ileum, taking into
account the disappearance of the test product in the lumen (Peff) and appearance in the mesenteric
circulation (Papp), are shown in Table 2.
Table 2. Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal
and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm
intestinal segment.
Test Compound Peff (× 10−5 cm/s) Papp (× 10−6 cm/s)
OLC 2.23 ± 3.16 4.12 * ± 2.33
LEV 7.64 ± 5.55 10.91 ± 6.27
* p < 0.05, Mann–Whitney U-test.
In Figure 5, the mean cumulative transport of OLC (A) and LEV (B), corrected for the length of
the perfused segment, is illustrated as a function of time.
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Figure 5. Transport of oleocanthal (OLC) (right Y-axis scale) and levofloxacin (left Y-axis scale) from
the intestinal lumen to the mesenteric blood. Cumulative amount values are normalised to a 10-cm
intestinal segment. Results are expressed as the mean ± standard deviation.
The difference between Peff vs. Papp values is common in these types of studies; it has even been
observed for theophylline where an absence of mass balance was observed, taking into account the
mass lost from the perfusate and mass appearance in portal plasma [39]. Drug transfer from the
lumen to the blood is not an instantaneous process: Peff only refers to the resistance to transport from
the lumen to the inside of the membrane, but not to the blood [40,41]. During the transport from
the intestinal wall to the blood, different processes can occur, including accumulation in gut tissue,
binding to transporters, gut wall metabolism, binding to red blood cells, and lymphatic transport [39].
Moreover, the rate of appearance in blood may be markedly dependent upon the blood flow rate. The
difference in LEV values can be attributed to P-glycoprotein (P-gp) binding [42,43] and in the case of
OLC, to microbiota and gut wall metabolism, according to the results reported in the previous section
(Section 3.1). Moreover, as shown in Figure 5, the two compounds presented different accumulation
profiles in mesenteric blood, with a lag time observed for OLC. This lag could be explained by the
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transit time in gut tissue due to phase I and phase II metabolic reactions in the enterocytes, which
would delay appearance in the blood.
In our study, the decrease in concentration of LEV in the lumen samples was very low, resulting in
lower absorption and permeability coefficient than expected. This low permeability could be attributed
to LEV acting as a substrate for the efflux transporter P-gp, which would secrete the absorbed drug to
the intestinal lumen. However, this finding observed in our in vivo study did not translate into a lower
value of the apparent permeability coefficient in a study by Volpe [33] in in vitro Caco-2 cells, where a
Papp (apical-basolateral direction) similar to the highly permeable standard metoprolol was obtained.
Nevertheless, in this study, the values of Papp obtained for OLC are lower (p < 0.05) than for LEV.
The lower extent of absorption is also reflected in the AUC calculated from the plasma concentrations
in mesenteric blood (normalized by the input concentration). The lower OLC AUC values (AUC
0.25 ± 0.04 vs. 0.635 ± 0.03 for OLC and LEV, respectively) confirm that the intestinal membrane
had low permeability for OLC, although its physicochemical characteristics (logP = 1.15 and MW
304.34 g/mol) were not unfavourable for its absorption. The poor absorption of OLC in our experimental
conditions (perfusion flow rate 1 mL/min), as well as its presence in the ileum (located next to the
caecum, where bacterial density is high), could favour microbiome metabolism. Both circumstances,
low absorption and high intestinal metabolism, can lead to incomplete bioavailability through a variety
of mechanisms, including pre-systemic gastrointestinal and hepatic first-pass metabolism, saturation of
carrier-mediated uptake processes, a low permeability constant, and P-gp-mediated transport out of the
epithelial cells back into the lumen of the gastrointestinal tract [44]. According to its physicochemical
properties (low solubility and relatively high lipophilicity), this compound meets the characteristics of
BCS class 2. For these compounds, efflux transporters can affect their extent and rate of absorption [45],
as observed in our study. The hypothesis that OLC could be a P-gp substrate should not be discarded,
but more studies are needed to confirm it.
It should be noted that the human Peff estimated for drugs transported by passive diffusion is,
on average, 3.6 times higher in human in vivo than in rat in situ [11]; thus, higher levels of OLC are
expected to reach human plasma.
4. Conclusions
In conclusion, OLC is a phenolic compound with an incomplete oral bioavailability due to its
relatively low absorption (16%) and high intestinal metabolism. Its poor absorption was indicated by a
low effective permeability coefficient, apparent permeability coefficient and area under the mesenteric
blood–time curve normalized by the inlet concentration in comparison with the reference standard
compound LEV. However, previous research has indicated that higher levels of OLC reach human
plasma than in rats [11]. Regarding the metabolic profile, OLC was mostly metabolised by phase I
hydration reactions. Hydrogenation and hydroxylation were also observed, and the hydrogenated
and hydrated metabolites were then glucuronidated in phase II reactions.
This is the first in vivo study in rats to simultaneously assess the absorption and intestinal
metabolism of OLC. Given the importance of phenolic compounds from EVOO, especially OLC
on human health and its demonstrated moderated ability to be transported through the intestinal
membrane, the development of dietary supplements containing OLC and excipients that favour
their immediate release and absorption in the gastrointestinal tract should be considered, especially
for populations with low intake of EVOO. In addition, further studies on OLC oral absorption and
bioavailability are necessary, as well as studies on the biological relevance of the most abundant
OLC metabolites.
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